These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37419768)

  • 41. Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
    Ashraf S; Ashraf S; Farooq I; Ashraf S; Ashraf M; Imran MA; Kalsoom L; Akmal R; Ghufran M; Rafique S; Akram MK; Habib Z; Siddiqui UN; Ahmad A; Arshad S; Virk MAR; Gul M; Awais AB; Hassan M; Sherazi SSH; Safdar Z; Munir I; Khalid H; Munir K; Majeed N; Alahmadi YM; Humayun A; Saboor QA; Ahmad A; Ashraf M; Izhar M;
    Trials; 2021 Sep; 22(1):591. PubMed ID: 34488858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: a double-blind randomised controlled trial.
    Seely D; Legacy M; Conte E; Keates C; Psihogios A; Ramsay T; Fergusson DA; Kanji S; Simmons JG; Wilson K
    BMJ Open; 2023 Sep; 13(9):e073761. PubMed ID: 37739466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit: A structured summary of a study protocol for a randomized controlled trial.
    Ameri A; Asadi MF; Kamali M; Vatankhah M; Ziaei A; Safa O; Mahmudi M; Fathalipour M
    Trials; 2021 Mar; 22(1):194. PubMed ID: 33685474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
    Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Homeopathy for Covid-19 in Primary Care: A structured summary of a study protocol for a randomized controlled trial.
    Adler UC; Adler MS; Hotta LM; Padula AEM; de Toledo Cesar A; Diniz JNM; Mestre CAA; Spiller KR; Soares L; de Freitas Santos H; Martinez EZ
    Trials; 2021 Feb; 22(1):109. PubMed ID: 33522951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial.
    Farnoosh G; Akbariqomi M; Badri T; Bagheri M; Izadi M; Saeedi-Boroujeni A; Rezaie E; Ghaleh HEG; Aghamollaei H; Fasihi-Ramandi M; Hassanpour K; Alishiri G
    Arch Med Res; 2022 Jan; 53(1):79-85. PubMed ID: 34229896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.
    Murai IH; Fernandes AL; Sales LP; Pinto AJ; Goessler KF; Duran CSC; Silva CBR; Franco AS; Macedo MB; Dalmolin HHH; Baggio J; Balbi GGM; Reis BZ; Antonangelo L; Caparbo VF; Gualano B; Pereira RMR
    JAMA; 2021 Mar; 325(11):1053-1060. PubMed ID: 33595634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial.
    Lamas GA; Boineau R; Goertz C; Mark DB; Rosenberg Y; Stylianou M; Rozema T; Nahin RL; Lindblad L; Lewis EF; Drisko J; Lee KL;
    Ann Intern Med; 2013 Dec; 159(12):797-805. PubMed ID: 24490264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial.
    Natarajan S; Anbarasi C; Sathiyarajeswaran P; Manickam P; Geetha S; Kathiravan R; Prathiba P; Pitchiahkumar M; Parthiban P; Kanakavalli K; Balaji P
    Trials; 2020 Oct; 21(1):892. PubMed ID: 33109252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
    Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
    Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
    Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
    Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.
    Nickols NG; Mi Z; DeMatt E; Biswas K; Clise CE; Huggins JT; Maraka S; Ambrogini E; Mirsaeidi MS; Levin ER; Becker DJ; Makarov DV; Adorno Febles V; Belligund PM; Al-Ajam M; Muthiah MP; Montgomery RB; Robinson KW; Wong YN; Bedimo RJ; Villareal RC; Aguayo SM; Schoen MW; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Orshansky G; Norman LE; Tran S; Ghayouri L; Tsai S; Geelhoed M; Rettig MB
    JAMA Netw Open; 2022 Apr; 5(4):e227852. PubMed ID: 35438754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: Multicentre randomized controlled clinical trial.
    Mariani J; Antonietti L; Tajer C; Ferder L; Inserra F; Sanchez Cunto M; Brosio D; Ross F; Zylberman M; López DE; Luna Hisano C; Maristany Batisda S; Pace G; Salvatore A; Hogrefe JF; Turela M; Gaido A; Rodera B; Banega E; Iglesias ME; Rzepeski M; Gomez Portillo JM; Bertelli M; Vilela A; Heffner L; Annetta VL; Moracho L; Carmona M; Melito G; Martínez MJ; Luna G; Vensentini N; Manucha W
    PLoS One; 2022; 17(5):e0267918. PubMed ID: 35622854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Safa O; Hassaniazad M; Farashahinejad M; Davoodian P; Dadvand H; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):841. PubMed ID: 33036662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.